Global Glioblastoma Multiforme Treatment Market : Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

November 2017 | 216 pages | ID: G36AEDA1B09EN
Precision Business Insights (PBI)

Abstracts

Global Glioblastoma Multiforme Treatment Market

Glioblastoma multiforme is the high-grade glioma and potent malignant brain tumor that affects glial cells. Glioblastoma multiforme contains the complexly differentiated neoplastic astrocytes which are the subtype of central nervous system. Glioblastoma multiforme is different from the anaplastic astrocytoma due to the presence of hyperplastic blood vessels and necrotic tissue. The glioblastoma multiforme is diagnosed by using the imaging modules namely, positron emission tomography (PET), magnetic resonance imaging (MRI), and computed tomography (CT). Glioblastoma multiforme is classified into two types namely, gliosarcoma and giant cell glioblastoma. Gliomas are the tumors emerge from glial cells and might occur in brain or the spinal cord. The common symptoms observed in the patients suffering from glioblastoma multiforme include nausea, headache, seizure, memory loss, and hemiparesis, among others.

The global glioblastoma multiforme treatment market is growing at a significant CAGR due to increase in the geriatric population, and changes in the lifestyle. The increase in alcohol consumption, a rise in malaria prevalence, and the increase in the incidence of seizures are the key factors driving the global glioblastoma multiforme treatment market. Furthermore, increase in research and development in gene therapy, molecular biotechnology for the treatment of CNS associated disorders, urgent need of alternative treatment procedures due to the resistance of glioma cells to conventional therapies are anticipated to boost the glioblastoma multiforme treatment market over the forecast period. However, major restraints of the glioblastoma multiforme treatment market are current treatment therapies such as radiation and chemotherapy does not prevent tumour recurrence that causes death in glioblastoma multiforme patients. Similarly, high expenditure for the genomics-based research, less number of drugs available in the market, and the high cost of treatment are expected to hinder the glioblastoma multiforme treatment market growth over the forecast period.

Global Glioblastoma multiforme treatment market is segmented based on the drug type, and end user

Based on the drug type, glioblastoma multiforme treatment market has segmented into the following:

• Temozolomide
• Bevacozumab
• carmustine
• Radiosensitizers
• Others

Based on the distribution channel, the glioblastoma treatment drug market has segmented into following:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Increase in prevalence of brain tumours (According to U.S. National Cancer Institute (NCI) glioblastoma multiforme is considered as the most aggressive form of brain cancer with 15.4% of all primary brain tumours and about 60% – 75% of all astrocytoma) driving the growth of glioblastoma multiforme treatment market. Moreover, various drugs under clinical trials like CDX-110 (manufactured by Celldex Therapeutics) (Phase 3) and DCVax (Northwest Biotherapeutics) (Phase 3) expected to fuel growth of glioblastoma multiforme treatment market. Rising product approvals from U.S. Food and Drug Administration (FDA) also expected to drive revenue of glioblastoma treatment market. For instance, in March 2005, U.S. Food and Drug Administration (FDA) approved temozolomide (Temodar) capsules, developed by Schering Corporation (Merck & Co., Inc.) to treat newly diagnosed patients with glioblastoma multiforme disease associated with radiotherapy and then as maintenance treatment. Similarly, entry of generics into the market also increases the growth of glioblastoma multiforme treatment market. For instance, in 2013, Teva Pharmaceutical Industries Ltd, and Sun Pharmaceutical Industries Ltd. entered the market with the generic version of temozolomide.

Geographically, the glioblastoma multiforme treatment market segmented into following regions Viz. North America, Asia-Pacific, Europe, Middle East & Africa, and Latin America. North America dominates the glioblastoma multiforme treatment market followed by Europe and Asia-Pacific North America region growth is attributed to increase in the prevalence of glioblastoma multiforme disease (According to Centres for Disease Control and Prevention (CDC), in 2011, approximately 22,000 adults in the U.S. were diagnosed with primary malignant tumours of the brain and spinal cord out of which gliomas accounted for the highest rate of incidence), investments in research and development, and increasing CNS cancers in aging population. Company’s betting heavily on research activities due to lack of drugs to treat glioblastoma multiforme in the market. Similarly, National Brain Tumour Society, Brain Tumour Foundation of Canada, and American Brain Tumour Association are the health organizations engaged in raising awareness about glioblastoma multiforme leads to the growth of glioblastoma multiforme treatment market over the forecast period. Europe glioblastoma multiforme treatment market revenue growth is driven by increase in geriatric population, change in lifestyle and increase in research and development activities by various pharmaceutical companies. Asia-Pacific is expected to be the fastest growing market over the forecast period as a result of improving healthcare infrastructure, and rising awareness of glioblastoma multiforme treatment. Furthermore, extensive use of genomic profiling in bioinformatics technology by the research and development firms in Asia-Pacific region is expected to drive the treatment market for nervous carcinoma by discovering the new drug targets.

Some of the players in glioblastoma multiforme treatment market are Merck & Co Inc. (U.S.), Teva Pharmaceutical Industries, Ltd. (Israel), Arbor Pharmaceuticals LLC. (U.S.), Sun Pharmaceutical Industries, Ltd. (India), F. Hoffmann-Le Roche Ltd. (Switzerland), Abbvie, Inc. (U.S.), Celldex Therapeutics, Inc. (U.S.), Exellixis, Inc. (U.S.), Bristol-Myers Squibb Co. (U.S.), AstraZeneca (U.K.), GlaxoSmithKline plc. (U.K.), CANbridge Life Sciences Ltd. (China), Apogenix (Germany), Pfizer, Inc. (U.S.), and Vascular Biogenics (Israel) to name a few.

In August 2015, VBL Therapeutics announced the first patient dosed in pivotal Phase 3 trial of VB-111 in recurrent glioblastoma

In July 2015, CANbridge Life Sciences acquired license for to develop, manufacture and commercialize Apogenix’s APG101 onco-immunotherapy in glioblastoma for China

Report Outline:

• The report provides granular level information about the market size, regional market share and forecast from 2017-2023
• The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
• The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
• The report tracks recent innovations, key developments and startup’s details that are working in the industry
• The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET INTRODUCTION

2.1. Global Glioblastoma Multiforme Treatment Market – Taxonomy
2.2. Global Glioblastoma Multiforme Treatment Market –Definitions
  2.2.1. Drug Type
  2.2.2. Distribution Channel

3. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET DYNAMICS

3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Glioblastoma Multiforme Treatment Market Dynamics – Factors Impact Analysis
3.6. Global Glioblastoma Multiforme Treatment Market – Regulations
  3.6.1. U.S
  3.6.2. Europe
  3.6.3. Japan
  3.6.4. China
3.7. Global Glioblastoma Multiforme Treatment Market – Product Innovations

4. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis

5. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Temozolomide
  5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  5.1.3. Market Opportunity Analysis
5.2. Bevacozumab
  5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  5.2.3. Market Opportunity Analysis
5.3. Carmustine
  5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  5.3.3. Market Opportunity Analysis
5.4. Radiosensitizers
  5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  5.4.3. Market Opportunity Analysis
5.5. Others
  5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  5.5.3. Market Opportunity Analysis

6. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Retail Pharmacies
  6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  6.1.3. Market Opportunity Analysis
6.2. Hospital Pharmacies
  6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  6.2.3. Market Opportunity Analysis
6.3. Online Pharmacies
  6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  6.3.3. Market Opportunity Analysis

7. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. North America
  7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  7.1.3. Market Opportunity Analysis
7.2. Europe
  7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  7.2.3. Market Opportunity Analysis
7.3. Asia-Pacific
  7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  7.3.3. Market Opportunity Analysis
7.4. Latin America
  7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
  7.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  7.5.3. Market Opportunity Analysis
7.6. Global Glioblastoma Multiforme Treatment Market - Opportunity Analysis Index, By Drug Class, Distribution Channel and Region, 2017 – 2023

8. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  8.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    8.1.1.1. Temozolomide
    8.1.1.2. Bevacozumab
    8.1.1.3. carmustine
    8.1.1.4. Radiosensitizers
    8.1.1.5. Others
  8.1.2. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    8.1.2.1. Retail Pharmacies
    8.1.2.2. Hospital Pharmacies
    8.1.2.3. Online Pharmacies
  8.1.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
    8.1.3.1. U.S.
    8.1.3.2. Canada
  8.1.4. North America Glioblastoma Multiforme Treatment Market - Opportunity Analysis Index, By Drug Analysis, Distribution Channel, and Country, 2017 – 2023
  8.1.5. North America Glioblastoma Multiforme Treatment Market Dynamics – Trends

9. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  9.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    9.1.1.1. Temozolomide
    9.1.1.2. Bevacozumab
    9.1.1.3. carmustine
    9.1.1.4. Radiosensitizers
    9.1.1.5. Others
  9.1.2. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    9.1.2.1. Retail Pharmacies
    9.1.2.2. Hospital Pharmacies
    9.1.2.3. Online Pharmacies
  9.1.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    9.1.3.1. Germany
    9.1.3.2. UK
    9.1.3.3. France
    9.1.3.4. Spain
    9.1.3.5. Italy
    9.1.3.6. Russia
    9.1.3.7. Poland
    9.1.3.8. Rest of Europe
  9.1.4. Europe Glioblastoma Multiforme Treatment Market - Opportunity Analysis Index, By Drug Analysis, Distribution Channel and Country, 2017 – 2023
  9.1.5. Europe Glioblastoma Multiforme Treatment Market Dynamics – Trends

10. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  10.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    10.1.1.1. Temozolomide
    10.1.1.2. Bevacozumab
    10.1.1.3. carmustine
    10.1.1.4. Radiosensitizers
    10.1.1.5. Others
  10.1.2. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.2.1. Retail Pharmacies
    10.1.2.2. Hospital Pharmacies
    10.1.2.3. Online Pharmacies
  10.1.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
    10.1.3.1. Japan
    10.1.3.2. China
    10.1.3.3. India
    10.1.3.4. ASEAN
    10.1.3.5. Australia & New Zealand
    10.1.3.6. Rest of Asia-Pacific
  10.1.4. Asia-Pacific Glioblastoma Multiforme Treatment Market - Opportunity Analysis Index, By Drug Analysis, Distribution Channel and Country, 2017 – 2023
  10.1.5. Europe Glioblastoma Multiforme Treatment Market Dynamics – Trends

11. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  11.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    11.1.1.1. Temozolomide
    11.1.1.2. Bevacozumab
    11.1.1.3. carmustine
    11.1.1.4. Radiosensitizers
    11.1.1.5. Others
  11.1.2. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.2.1. Retail Pharmacies
    11.1.2.2. Hospital Pharmacies
    11.1.2.3. Online Pharmacies
  11.1.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.3.1. Brazil
    11.1.3.2. Mexico
    11.1.3.3. Argentina
    11.1.3.4. Venezuela
    11.1.3.5. Rest of Latin America
  11.1.4. Latin America Glioblastoma Multiforme Treatment Market - Opportunity Analysis Index, By Drug Analysis, Distribution Channel and Country, 2017 – 2023
  11.1.5. Latin America Glioblastoma Multiforme Treatment Market Dynamics – Trends

12. MIDDLE EAST AND AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  12.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    12.1.1.1. Temozolomide
    12.1.1.2. Bevacozumab
    12.1.1.3. carmustine
    12.1.1.4. Radiosensitizers
    12.1.1.5. Others
  12.1.2. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.2.1. Retail Pharmacies
    12.1.2.2. Hospital Pharmacies
    12.1.2.3. Online Pharmacies
  12.1.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    12.1.3.1. Gulf Cooperation Council (GCC) Countries
    12.1.3.2. Israel
    12.1.3.3. South Africa
    12.1.3.4. Rest of MEA
  12.1.4. MEA Glioblastoma Multiforme Treatment Market - Opportunity Analysis Index By Drug Analysis, Distribution Channel and Country, 2017 – 2023
  12.1.5. MEA Glioblastoma Multiforme Treatment Market Dynamics – Trends

13. COMPETITION LANDSCAPE

13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  13.2.1. Pfizer, Inc. (U.S)
  13.2.2. Allergan Inc. (Ireland)
  13.2.3. Boehringer Ingelheim GmbH (Germany)
  13.2.4. CIBA Vision Ophthalmics (U.S)
  13.2.5. Sanofi (France)
  13.2.6. Novartis AG (Switzerland)
  13.2.7. Bausch & Lomb Inc. (Valeant) (Canada)
  13.2.8. Merck & Co., Inc. (U.S)
  13.2.9. Santen Pharmaceuticals Co. Ltd.(Japan)

14. RESEARCH METHODOLOGY

15. KEY ASSUMPTIONS AND ACRONYMS